胱抑素C测量在慢性肾脏病诊断与管理中的临床效用与成本影响:一项初级保健队列研究
该研究在初级保健队列中评估了基于胱抑素C的eGFR(eGFRcys)在慢性肾脏病(CKD)G3aA1患者中确认或排除诊断的临床效用与成本影响。结果显示eGFRcys将7.7%的CKD G3aA1患者重分类为无CKD,但将59.0%重分类为更严重CKD,且未改善风险预测并增加监测成本。作者认为数据不支持在初级保健中实施现行指南推荐。
要点
- eGFRcys将7.7%的CKD G3aA1患者重分类为eGFR≥60 ml/min/1.73 m2
- eGFRcys将59.0%的CKD G3aA1患者重分类为更严重CKD
- eGFRcys未改善CKD进展和全因死亡的风险预测,且增加监测成本
核心结论
- 在初级保健老年人群中实施现行eGFRcys检测指南仅小幅减少CKD诊断,但将更大比例分类为更严重CKD。
- 使用eGFRcys未改善风险预测且与成本增加相关,数据不支持在初级保健中实施这些推荐。
- 需进一步研究以确定eGFRcys和eGFRcreat-cys最合适的临床应用。
研究设计与样本
- 研究为初级保健队列研究,纳入2008年6月至2010年3月期间招募的1741名CKD G3a或G3b患者,定义为两次eGFR值间隔超过90天。
- 使用CKD-EPI方程比较基线及5年随访期间eGFRcreat、eGFRcys和eGFRcreat-cys。
主要发现
- 平均eGFRcys为45.1 ml/min/1.73 m2(95% CI 44.4至45.9),显著低于平均eGFRcreat 53.6 ml/min/1.73 m2(95% CI 53.0至54.1),P < 0.001。
- eGFRcys将7.7%(50/653)的eGFRcreat定义的CKD G3aA1患者重分类为eGFR≥60 ml/min/1.73 m2,将59.0%(385/653)重分类为更严重CKD。
- 使用eGFRcreat-cys呈现相似模式但重分类比例较低。
- 5年内eGFRcreat与eGFRcys变化弱相关(r = 0.33,P < 0.001),但eGFRcys识别更多CKD进展者(18.2% vs 10.5%)。
- 使用eGFRcys或eGFRcreat-cys的风险预测模型在CKD进展和全因死亡判别力上未优于eGFRcreat模型。
关键数值与推荐
- eGFRcys重分类CKD G3aA1至无CKD比例:7.7%(50/653);至更严重CKD比例:59.0%(385/653)。
- 平均eGFRcys 45.1 ml/min/1.73 m2(95% CI 44.4至45.9) vs 平均eGFRcreat 53.6 ml/min/1.73 m2(95% CI 53.0至54.1),P < 0.001。
- eGFRcys识别CKD进展比例18.2% vs eGFRcreat 10.5%。
- 应用NICE指南至CKD G3aA1参与者增加监测成本每患者£23, extrapolated to England增加约£31 million per year。
临床怎么用
- 作者认为数据不支持在初级保健中实施现行eGFRcys检测推荐。
- 原文未据此给出推荐。
局限性
- 研究缺乏测量的GFR。
- 研究队列可能缺乏民族多样性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To reduce over-diagnosis of chronic kidney disease (CKD) resulting from the inaccuracy of creatinine-based estimates of glomerular filtration rate (GFR), UK and international guidelines recommend that cystatin-C-based estimates of GFR be used to confirm or exclude the diagnosis in people with GFR 45-59 ml/min/1.73 m2 and no albuminuria (CKD G3aA1). Whilst there is good evidence for cystatin C being a marker of GFR and risk in people with CKD, its use to define CKD in this manner has not been evaluated in primary care, the setting in which most people with GFR in this range are managed. METHODS AND FINDINGS: A total of 1,741 people with CKD G3a or G3b defined by 2 estimated GFR (eGFR) values more than 90 days apart were recruited to the Renal Risk in Derby study between June 2008 and March 2010. Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations, we compared GFR estimated from creatinine (eGFRcreat), cystatin C (eGFRcys), and both (eGFRcreat-cys) at baseline and over 5 years of follow-up. We analysed the proportion of participants with CKD G3aA1 reclassified to 'no CKD' or more advanced CKD with the latter two equations. We further assessed the impact of using cystatin-C-based eGFR in risk prediction equations for CKD progression and all-cause mortality and investigated non-GFR determinants of eGFRcys. Finally, we estimated the cost implications of implementing National Institute for Health and Care Excellence (NICE) guidance to use eGFRcys to confirm the diagnosis in people classified as CKD G3aA1 by eGFRcreat. Mean eGFRcys was significantly lower than mean eGFRcreat (45.1 ml/min/1.73 m2, 95% CI 44.4 to 45.9, versus 53.6 ml/min/1.73 m2, 95% CI 53.0 to 54.1, P < 0.001). eGFRcys reclassified 7.7% (50 of 653) of those with CKD G3aA1 by eGFRcreat to eGFR ≥ 60 ml/min/1.73 m2. However, a much greater proportion (59.0%, 385 of 653) were classified to an eGFR category indicating more severe CKD. A similar pattern was seen using eGFRcreat-cys, but lower proportions were reclassified. Change in eGFRcreat and eGFRcys over 5 years were weakly correlated (r = 0.33, P < 0.001), but eGFRcys identified more people as having CKD progression (18.2% versus 10.5%). Multivariable analysis using eGFRcreat as an independent variable identified age, smoking status, body mass index, haemoglobin, serum uric acid, serum albumin, albuminuria, and C reactive protein as non-GFR determinants of eGFRcys. Use of eGFRcys or eGFRcreat-cys did not improve discrimination in risk prediction models for CKD progression and all-cause mortality compared to similar models with eGFRcreat. Application of the NICE guidance, which assumed cost savings, to participants with CKD G3aA1 increased the cost of monitoring by £23 per patient, which if extrapolated to be applied throughout England would increase the cost of testing and monitoring CKD by approximately £31 million per year. Limitations of this study include the lack of a measured GFR and the potential lack of ethnic diversity in the study cohort. CONCLUSIONS: Implementation of current guidelines on eGFRcys testing in our study population of older people in primary care resulted in only a small reduction in diagnosed CKD but classified a greater proportion as having more advanced CKD than eGFRcreat. Use of eGFRcys did not improve risk prediction in this population and was associated with increased cost. Our data therefore do not support implementation of these recommendations in primary care. Further studies are warranted to define the most appropriate clinical application of eGFRcys and eGFRcreat-cys.
引用
- Shardlow A, McIntyre NJ, Fraser SDS, et al. The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. PLoS Med. 2017. PMID: 29016597. doi:10.1371/journal.pmed.1002400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。